Durvalumab: all 557 studies that test it

Page 3 of 6. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.

• Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03026062Phase 2Results posted
• Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on ChemotherapyCompletedNCT03007407Phase 2Results posted
• Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)Active, not recruitingNCT03003962Phase 3Results posted
• A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03000452Phase 2Results posted
• A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal MalignanciesCompletedNCT02963831Phase 1/2Results posted
• Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 MutationCompletedNCT02953457Phase 2Results posted
• Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the BladderTerminatedNCT02901548Phase 2Results posted
• Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable MesotheliomaCompletedNCT02899195Phase 2Results posted
• Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung CancerCompletedNCT02898116Phase 1/2Results posted
• Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the BladderTerminatedNCT02891161Phase 1/2Results posted
• A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer PatientsCompletedNCT02879617Phase 2Results posted
• Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic AdenocarcinomaCompletedNCT02879318Phase 2Results posted
• Durvalumab and Tremelimumab in Patients With Advanced Rare TumoursCompletedNCT02879162Phase 2Results posted
• Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal CancerCompletedNCT02870920Phase 2Results posted
• Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx CancerTerminatedNCT02827838Early Phase 1Results posted
• Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma SubtypesCompletedNCT02815995Phase 2Results posted
• An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)CompletedNCT02775903Phase 2Results posted
• Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersCompletedNCT02766335Phase 2/3Results posted
• TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian CancerCompletedNCT02764333Phase 2Results posted
• Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by SurgeryCompletedNCT02754856Phase 1Results posted
• A Study of LY2510924 and Durvalumab in Participants With Solid TumorsTerminatedNCT02737072Phase 1Results posted
• A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid TumorsCompletedNCT02718911Phase 1Results posted
• Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell TransplantTerminatedNCT02716805Phase 1Results posted
• JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT02706405Phase 1Results posted
• A Study of Durvalumab (MEDI4736) and Monalizumab in Solid TumorsActive, not recruitingNCT02671435Phase 1/2Results posted
• MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived TumorsTerminatedNCT02669914Phase 2Results posted
• A Study of Durvalumab (MEDI4736) in Esophageal CancerCompletedNCT02639065Phase 2Results posted
• MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural MesotheliomaCompletedNCT02592551Phase 2Results posted
• Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)CompletedNCT02572843Phase 2Results posted
• Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal CarcinomaCompletedNCT02558894Phase 2Results posted
• Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck CancerCompletedNCT02551159Phase 3Results posted
• Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)Active, not recruitingNCT02542293Phase 3Results posted
• MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast CancerCompletedNCT02536794Phase 2Results posted
• A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaActive, not recruitingNCT02519348Phase 2Results posted
• Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial CancerActive, not recruitingNCT02516241Phase 3Results posted
• Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & NeckCompletedNCT02499328Phase 1/2Results posted
• A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung CancerCompletedNCT02492867Not applicableResults posted
• Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast CancerCompletedNCT02489448Phase 1/2Results posted
• Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive TumoursCompletedNCT02454933Phase 3Results posted
• Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)Active, not recruitingNCT02453282Phase 3Results posted
• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid TumorsCompletedNCT02403271Phase 1/2Results posted
• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory LymphomasCompletedNCT02401048Phase 1/2Results posted
• Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck CancerCompletedNCT02369874Phase 3Results posted
• A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT02352948Phase 3Results posted
• A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ AdenocarcinomaCompletedNCT02340975Phase 1/2Results posted
• Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and NeckCompletedNCT02319044Phase 2Results posted
• A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)CompletedNCT02318277Phase 1/2Results posted
• Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic CancerCompletedNCT02311361Phase 1/2Results posted
• Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic SyndromesCompletedNCT02281084Phase 2Results posted
• Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCCompletedNCT02273375Phase 3Results posted
• Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal CancerCompletedNCT02227667Phase 2Results posted
• Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02207530Phase 2Results posted
• A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal AntibodiesTerminatedNCT02205333Phase 1/2Results posted
• A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerCompletedNCT02125461Phase 3Results posted
• A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced MalignanciesCompletedNCT02118337Phase 1/2Results posted
• A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT02087423Phase 2Results posted
• A Phase 1 Study to Evaluate MEDI4736 in Combination With TremelimumabCompletedNCT01975831Phase 1Results posted
• A Phase 1/2 Study to Evaluate MEDI4736CompletedNCT01693562Phase 1/2Results posted
• Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT07081633Phase 2
• A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular CarcinomaWithdrawnNCT06994299Phase 2
• Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.Active, not recruitingNCT06992609Phase 3
• Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and TremelimumabActive, not recruitingNCT06710223Phase 1
• Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)SuspendedNCT06694454Phase 1/2
• BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular CarcinomaWithdrawnNCT06608940Phase 1/2
• A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Active, not recruitingNCT06606847Phase 2
• Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid CarcinomaCompletedNCT06446570Phase 2
• Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV InfectionWithdrawnNCT06245291Phase 2
• A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)Active, not recruitingNCT06218511Phase 1
• --SuPERIOR Trial--TerminatedNCT06191250Phase 2
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerActive, not recruitingNCT06112379Phase 3
• NEO-adjuvant Chemo-immunotherapy in Pancreatic CancerActive, not recruitingNCT06094140Phase 2
• Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT06083454Phase 1
• Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before SurgerySuspendedNCT06050252Phase 2
• A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TAREActive, not recruitingNCT06040099Phase 2
• DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)Active, not recruitingNCT06027086Phase 1/2
• Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic CholangiocarcinomaWithdrawnNCT06017297Phase 2
• A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASActive, not recruitingNCT06008093Phase 2
• BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC ParticipantsActive, not recruitingNCT05943106Phase 3
• A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 2
• Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy EfficacyActive, not recruitingNCT05927142Phase 1/2
• Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)Active, not recruitingNCT05925530Phase 2
• A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)CompletedNCT05924880Phase 3
• Abequolixron (RGX-104) and Durvalumab in Lung CancerTerminatedNCT05911308Phase 1
• Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT05883644Phase 3
• Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)Active, not recruitingNCT05856695Phase 2
• A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C MutationsWithdrawnNCT05848843Phase 1
• Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic RadiotherapyActive, not recruitingNCT05796089Phase 2
• Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)Active, not recruitingNCT05771480Phase 3
• Using Circulating Tumor DNA to Personalize Duration of Consolidation DurvalumabWithdrawnNCT05757843Phase 2
• Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical SurgeryActive, not recruitingNCT05713838Phase 2
• Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT05687266Phase 3
• Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes AlterationsActive, not recruitingNCT05659914Phase 2
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)Active, not recruitingNCT05629585Phase 3
• Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the ThoraxActive, not recruitingNCT05617963Phase 2
• Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCActive, not recruitingNCT05557838Phase 3
• A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid TumoursActive, not recruitingNCT05514132Phase 1
• A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyActive, not recruitingNCT05450692Phase 3
• Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC RegimenTerminatedNCT05443971Phase 1
• Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic CancerActive, not recruitingNCT05411094Phase 1
• Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLCSuspendedNCT05403723Phase 1

← Durvalumab overview